Jazz Pharmaceuticals (JAZZ) Assets Average (2011 - 2026)
Jazz Pharmaceuticals' quarterly Assets Average came in at $11.8 billion in Q1 2026, little changed year-on-year from $11.8 billion in Q1 2025, and up 2.19% quarter-over-quarter from $11.5 billion in Q4 2025.
Jazz Pharmaceuticals has reported Assets Average for 16 years, with the latest figure at $11.8 billion in Q1 2026.
- For the quarter ending Q1 2026, Assets Average changed 0.12% year-over-year to $11.8 billion; the trailing twelve-month figure through Mar 2026 stood at $11.8 billion (changed 0.12% YoY), and the FY2025 full-year result was $11.8 billion, up 1.14% from the prior year.
- Assets Average for Q1 2026 stood at $11.8 billion, up from $11.5 billion in the prior quarter.
- The five-year high for Assets Average was $12.1 billion in Q4 2024, with the low at $10.6 billion in Q4 2022.
- Average Assets Average over 5 years is $11.4 billion, with a median of $11.3 billion recorded in 2024.
- Peak annual rise in Assets Average reached 81.06% in 2022, while the deepest fall reached 15.98% in 2022.
- Tracing JAZZ's Assets Average over 5 years: stood at $10.6 billion in 2022, then climbed by 6.49% to $11.3 billion in 2023, then rose by 7.39% to $12.1 billion in 2024, then declined by 5.16% to $11.5 billion in 2025, then increased by 2.19% to $11.8 billion in 2026.
- The last three Assets Average figures came in at $11.8 billion (Q1 2026), $11.5 billion (Q4 2025), and $11.2 billion (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 13.04 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 33.42 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 1.72 Bn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 331.70 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 40.89 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 26.06 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 26.03 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 40.71 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 5.05 Bn |
| 10 | Jazz Pharmaceuticals | 14.35 Bn | 12.51 Bn | 934.80 Mn | 11.76 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 11.76 Bn |
| Dec 31, 2025 | 11.51 Bn |
| Sep 30, 2025 | 11.15 Bn |
| Jun 30, 2025 | 11.24 Bn |
| Mar 31, 2025 | 11.77 Bn |
| Dec 31, 2024 | 12.13 Bn |
| Sep 30, 2024 | 11.81 Bn |
| Jun 30, 2024 | 11.34 Bn |
| Mar 31, 2024 | 11.36 Bn |
| Dec 31, 2023 | 11.30 Bn |
| Sep 30, 2023 | 11.23 Bn |
| Jun 30, 2023 | 11.15 Bn |
| Mar 31, 2023 | 10.94 Bn |
| Dec 31, 2022 | 10.61 Bn |
| Sep 30, 2022 | 10.79 Bn |
| Jun 30, 2022 | 11.48 Bn |
| Mar 31, 2022 | 12.03 Bn |
| Dec 31, 2021 | 12.39 Bn |
| Sep 30, 2021 | 12.85 Bn |
| Jun 30, 2021 | 9.98 Bn |
| Mar 31, 2021 | 6.65 Bn |
| Dec 31, 2020 | 6.41 Bn |
| Sep 30, 2020 | 6.18 Bn |
| Jun 30, 2020 | 5.64 Bn |
| Mar 31, 2020 | 5.38 Bn |
| Dec 31, 2019 | 5.53 Bn |
| Sep 30, 2019 | 5.51 Bn |
| Jun 30, 2019 | 5.38 Bn |
| Mar 31, 2019 | 5.24 Bn |
| Dec 31, 2018 | 5.34 Bn |
| Sep 30, 2018 | 5.42 Bn |
| Jun 30, 2018 | 5.32 Bn |
| Mar 31, 2018 | 5.21 Bn |
| Dec 31, 2017 | 5.06 Bn |
| Sep 30, 2017 | 4.90 Bn |
| Jun 30, 2017 | 4.81 Bn |
| Mar 31, 2017 | 4.81 Bn |
| Dec 31, 2016 | 4.87 Bn |
| Sep 30, 2016 | 4.19 Bn |
| Jun 30, 2016 | 3.49 Bn |
| Mar 31, 2016 | 3.43 Bn |
| Dec 31, 2015 | 3.40 Bn |
| Sep 30, 2015 | 3.43 Bn |
| Jun 30, 2015 | 3.32 Bn |
| Mar 31, 2015 | 3.29 Bn |
| Dec 31, 2014 | 3.34 Bn |
| Sep 30, 2014 | 3.25 Bn |
| Jun 30, 2014 | 3.18 Bn |
| Mar 31, 2014 | 2.72 Bn |
| Dec 31, 2013 | 2.21 Bn |
| Sep 30, 2013 | 2.14 Bn |
| Jun 30, 2013 | 2.05 Bn |
| Mar 31, 2013 | 1.99 Bn |
| Dec 31, 2012 | 1.85 Bn |
| Sep 30, 2012 | 1.71 Bn |
| Jun 30, 2012 | 1.30 Bn |
| Mar 31, 2012 | 574.47 Mn |
| Dec 31, 2011 | 230.69 Mn |
| Sep 30, 2011 | 200.61 Mn |